8-K: Soligenix Secures $3.45M At-The-Market Equity Facility

Soligenix, Inc. has entered into an At Market Issuance Sales Agreement with Rodman & Renshaw, LLC to potentially sell up to $3.45 million of common stock.

Summary

• Soligenix, Inc. entered into an At Market Issuance Sales Agreement with Rodman & Renshaw, LLC on January 23, 2026.
• The agreement allows the company to sell shares of its common stock, par value $0.001 per share, with an aggregate offering price of up to $3,450,000.
• Sales will be conducted from time to time, at the company's option, through Rodman & Renshaw, LLC as a sales agent, via at-the-market offerings on The Nasdaq Capital Market or other trading markets.
• The company retains control over the parameters for sales, including the number of shares, time period, daily sales limitations, and minimum price.
• Rodman & Renshaw, LLC will receive a fixed commission rate of up to 3.0% of the gross proceeds from the sale of shares.
• The Sales Agreement will terminate upon the earliest of December 15, 2026, the sale of all shares, termination by either party, or mutual agreement.
• The shares will be issued pursuant to the company's shelf registration statement on Form S-3 (File No. 333-274265), which was declared effective on December 15, 2023.

Sentiment

Score: 6

Explanation: The filing indicates a proactive step to secure flexible financing, which is generally positive for operational stability. However, it also introduces potential future dilution for shareholders, balancing the overall sentiment to moderately positive.

Positives

• Provides flexible access to capital of up to $3.45 million, allowing the company to raise funds as needed without a traditional underwritten offering.
• Allows management to control the timing and pricing of share sales, potentially minimizing market impact and adapting to favorable market conditions.
• Leverages an existing shelf registration statement, streamlining the fundraising process and reducing administrative burden.
• Secures potential funding for ongoing operations, research and development, and other general corporate purposes.

Negatives

• Potential for dilution for existing shareholders as new common stock is sold into the market.
• No assurance that the company will issue any shares or that the full $3.45 million will be raised.
• Market price fluctuations could impact the actual proceeds received by the company.
• A commission of up to 3.0% of gross proceeds will be paid to the sales agent, reducing net funds available to the company.

Risks

• The company cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement.
• The Sales Agreement may be terminated by either the company or Rodman & Renshaw, LLC, or at any time under certain circumstances, including a material adverse change in the company.
• Market conditions, trading suspensions, or other adverse financial or political developments could make it impracticable or inadvisable to market the Placement Shares.
• The issuance and sale of additional common stock will dilute the ownership interest of existing shareholders.

Future Outlook

The company may sell shares from time to time at its option, but provides no assurances regarding the issuance of any shares. This agreement provides a flexible financing tool to potentially raise capital for general corporate purposes, including research and development.

Management Comments

• The Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made.
• The Company has no obligation to sell any shares under the Sales Agreement, and may suspend solicitation and offers under the Sales Agreement.

Industry Context

At-the-market (ATM) offerings are a common and flexible financing tool, particularly for biotechnology and pharmaceutical companies like Soligenix, which often require ongoing capital for research and development, clinical trials, and general corporate purposes. This method allows companies to raise capital incrementally, adapting to market conditions and specific funding needs, rather than through a single, large, and potentially dilutive traditional offering.

Comparison to Industry Standards

• This At Market Issuance Sales Agreement is a standard financing mechanism widely used across various industries, especially in the biotechnology sector, for its flexibility in raising capital.
• Many small to mid-cap companies, including those with drug development pipelines, utilize ATMs to fund operations, clinical trials, or other strategic initiatives without the immediate, significant dilution or market disruption associated with a large, fixed-price offering.
• The structure and terms of this agreement, including the commission rate and termination clauses, are consistent with typical ATM agreements observed in the market for companies of similar size and industry.

Stakeholder Impact

• Shareholders: Potential for dilution as new shares are issued, but also provides funding for company operations which could support long-term value and strategic initiatives.
• Company Operations: Provides a flexible source of capital to fund ongoing research, development, clinical trials, and general corporate purposes, enhancing liquidity and financial stability.

Next Steps

• The company may, at its option, sell shares of common stock through Rodman & Renshaw, LLC.
• Rodman & Renshaw, LLC will use commercially reasonable efforts to sell the Placement Shares.
• The company will make required SEC filings, such as prospectus supplements, detailing shares sold and net proceeds.

Key Dates

Keywords

Soligenix, SNGX, At-The-Market, ATM offering, equity financing, capital raise, common stock, SEC filing, Form 8-K, Rodman & Renshaw, Nasdaq Capital Market